New Nordic announced plans on Monday to build a $4.1 billion facility in North Carolina, as demand for its popular weight-loss drugs has only increased in recent months.
The plant will be the Danish company’s second fill and finish production facility in Clayton, North Carolina, and fourth facility in the area overall.
Novo Nordisk — known for weight-loss and diabetes drugs Wegovy and Ozempic — said the new facility would expand by more than 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the others. three facilities in North Carolina.
Investment in biological sciences is the largest in the state’s history, Novo Nordisk he said. The company said it expects to add 1,000 new jobs, adding to the 2,500 in the region.
Construction of the facility will be gradually completed between 2027 and 2029, the company said, and “advance cleanup and foundation work is already underway.”
The goal, according to Novo Nordisk’s press release, is to expand the company’s capacity “to produce current and future injectable treatments for people with obesity and other serious chronic diseases.”
“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global manufacturing, we are building Novo Nordisk’s ability to serve millions more people living with serious chronic diseases in the future,” he said. Novo Nordisk President and CEO Lars Fruergaard Jørgensen said in the press release. “This is another real sign of our efforts to increase our production to meet the growing global need for our life-changing medicines and the patients of tomorrow.”
This story originally appeared on thehill.com read the full story
